PFIZER INC annual report, FY2016

Full document

Pfizer Inc. — 2016 Form 10-K

Reporting period: Fiscal year ended December 31, 2016. The filing is an annual report, not a standalone fourth-quarter report. The supplied text incorporates the full financial statements and detailed MD&A by reference but does not include them.

Business context and key metrics

  • Pfizer is a global biopharmaceutical company organized into Innovative Health (IH) and Essential Health (EH). Reported 2016 revenue was approximately $52.8 billion: IH approximately $29.2 billion and EH approximately $23.6 billion.
  • Research and development expense was approximately $7.9 billion. Pfizer sold products in more than 125 countries; non-U.S. revenue was $26.5 billion, or 50% of total revenue.
  • Eight direct-sale products and IH alliance revenue (primarily Eliquis) each exceeded $1 billion; together they represented 43% of total revenue.
  • As of December 31, 2016, Pfizer had approximately 96,500 employees and operated 63 manufacturing sites through Pfizer Global Supply.
  • The supplied filing text does not provide clear values for net income, operating income, EPS, cash flows, margins, total debt, cash balances, or liquidity ratios. Detailed financial statements are incorporated by reference.

Changes and transactions

  • Pfizer reorganized its commercial operations in 2016 into IH and EH; prior-period segment information was revised to reflect the change. The text does not provide a clear total-revenue or profit comparison with 2015.
  • Acquired Medivation on September 28, 2016, for approximately $14.3 billion in cash (approximately $13.9 billion net of acquired cash), and Anacor on June 24, 2016, for approximately $4.9 billion in cash (approximately $4.5 billion net of acquired cash), plus $698 million of assumed debt.
  • In December 2016, acquired rights to AstraZeneca’s small-molecule anti-infectives business for an upfront payment of approximately $550 million; further deferred, milestone, sales-related and royalty payments may apply.
  • On February 3, 2017, Pfizer completed the sale of its global infusion therapy net assets to ICU Medical for up to approximately $900 million, including cash, shares, seller financing and contingent consideration. This is a subsequent event, not a 2016 completed sale.
  • Essential Health products with direct sales above $1 billion declined from three in 2015 to two in 2016, while IH products in that category increased from five to six. These counts do not establish the direction of total segment revenue or profit.

Outlook, risks and unusual items

  • The filing refers to 2017 financial guidance in the incorporated 2016 Financial Report, but the supplied text does not provide the guidance figures.
  • Management said significant operating cash flows, financial assets, capital-market access and credit facilities support liquidity needs for the foreseeable future; no specific liquidity figures are provided here.
  • Key risks include generic and biosimilar competition, loss or challenge of patents, pricing and reimbursement pressure, dependence on leading products, R&D and regulatory uncertainty, foreign-exchange exposure, litigation, acquisition integration and manufacturing or supply disruptions.
  • In February 2017, Pfizer received an FDA warning letter concerning alleged current Good Manufacturing Practice violations at Hospira’s McPherson, Kansas facility. Corrective actions and discussions with the FDA were ongoing; the agency could withhold certain approvals or export certificates for products made there until issues are corrected.
  • Other uncertainties include potential U.S. changes to the Affordable Care Act, Brexit-related effects, and the ability to realize expected benefits from recent acquisitions and cost-reduction initiatives.
  • Environmental spending in 2016 included $27 million in capital expenditures and $126 million in other expenses. Pfizer said it did not expect these matters to materially affect capital expenditures or competitive position.

Investor verification priorities

  1. Review the incorporated consolidated financial statements and MD&A for earnings, EPS, cash flow, margins, debt, cash, and year-over-year comparisons.
  2. Check the 2017 guidance figures and assumptions in the 2016 Financial Report, including currency effects and expected product performance.
  3. Assess the acquired businesses’ contribution, purchase accounting, integration costs, and potential impairment exposure.
  4. Monitor patent litigation and exclusivity dates for major products, as well as competitive and payer-pricing developments.
  5. Track remediation and regulatory outcomes at the McPherson facility and any resulting effect on product supply.